[Clinical experience with etretinate (Tigason) in 26 patients with psoriasis].
The effect of etretinate was evaluated in 26 patients with psoriasis unresponsive to conventional therapy. Twenty patients had the common variety of the disease, 3 had inverse psoriasis, 2 had arthropathy and 1 had plantar psoriasis. In addition, 17 patients had nail involvement. The drug was started at dose of 0.6 mg/kg/day; and was adjusted according to clinical response over a mean period of 6.8 months. Disappearance of the plaque occurred in 14 patients (54%) and remained stable for a mean of 7.3 months after therapy. Success rate was higher in patients with nail involvement (80%). Results were good in patients with arthralgia associated to hyperuricemia, psoriatic arthropathy and in one patients with rheumatoid arthritis. Mild effects of vitamin A toxicity were observed in 100% of cases. The drug was discontinued in 4 patients due to hypertriglyceridemia.